logo
UT Health San Antonio researchers discover new links between heart disease and dementia

UT Health San Antonio researchers discover new links between heart disease and dementia

Yahoo2 days ago

Research led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has discovered new associations between various lipid, or fat, levels in the blood and the risk of developing Alzheimer's disease.
SAN ANTONIO, May 30, 2025 /PRNewswire-PRWeb/ -- People who are at higher risk for heart disease also seem more likely to develop dementia.
And research led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has discovered new associations between various lipid, or fat, levels in the blood and the risk of developing Alzheimer's disease, the most common cause of dementia worldwide.
The findings mean that using blood lipid profiles could help better understand, predict and possibly even prevent the disease in the future.
In more than 800 older adults who were part of the long-running Framingham Heart Study, the researchers found that higher levels of small dense cholesterol particles – which are known to increase the risk of atherosclerosis and coronary heart disease – were associated with higher risk of developing Alzheimer's disease.
However, higher levels of a marker for small fat-carrying particles, which are involved in the transport of dietary fats from the gut to other body tissues through the blood after eating, were associated with lower risk of developing the disease.
Perhaps ironically, the researchers also discovered that individuals who had the lowest levels of highly dense cholesterol particles – often referred to as "good cholesterol" as it is considered protective against cardiovascular disease – had a lower risk of developing Alzheimer's disease compared to the rest of the included individuals.
"These findings highlight the complex relationships of blood lipids with both heart and brain health, suggesting the possibility of certain blood lipids playing different roles in cardiovascular disease and dementia-related biological processes," said Sokratis Charisis, MD, a researcher with the Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases at UT Health San Antonio.
Charisis is first author of the study published May 30 in the journal Neurology, titled, "Association of Blood Lipoprotein Levels With Incident Alzheimer's Disease in Community-Dwelling Individuals: The Framingham Heart Study." Other authors include corresponding author Sudha Seshadri, MD, director of the Biggs Institute, and researchers from Boston University School of Public Health, the University of Texas Rio Grande Valley and the Framingham Heart Study.
A community-based analysis
The new study notes that dementia is a leading source of morbidity and mortality in the aging population. Worldwide, there were 57.4 million people living with dementia in 2019, a number that is expected to reach 152.8 million by 2050.
However, there is a general trend over time of decreasing incidence of Alzheimer's disease and other dementias in the U.S. and other higher-income countries that is at least partially attributed to better management of cardiovascular risk factors.
The Framingham Heart Study is an ongoing, community-based cohort study that was launched in 1948 in Framingham, Massachusetts. Residents there ages 30 to 59 were randomly selected from census data to participate. Those with definite signs of cardiovascular disease at baseline were excluded. Participants of the original cohort have undergone up to 32 examinations performed every two years, which have included detailed history-taking by a physician, a physical examination and lab testing.
The latest analysis by researchers led by UT Health San Antonio included participants from the original cohort who were 60 years or older and free of dementia during an examination period of 1985-1988, and had available cognitive follow-up and lipoprotein marker data. Lipoproteins act as a transport system for lipids in the bloodstream.
Blood lipid levels and dementia
Levels of high-density lipoprotein cholesterol (HDL-C), or good cholesterol; low-density lipoprotein cholesterol (LDL-C), or "bad cholesterol"; small dense LDL-C (sdLDL-C); and other lipoprotein types associated with heart disease were measured in blood samples obtained from the mid- to late-'80s examination period. The Framingham participants were watched for incident Alzheimer's disease, meaning a first diagnosis of the disease, until 2020.
Of a total of 822 participants, 128 developed incident Alzheimer's disease.
The researchers discovered that an increase of 1 standard deviation unit (SDU) of a concentration of small dense LDL-C (sdLDL-C), a value representing how far a specific data point deviates from the mean, was associated with a 21% increase in the risk for incident Alzheimer's disease.
As the name implies, small dense LDL-C (sdLDL-C) is a type of the so-called bad cholesterol with smaller and denser particles than other low-density lipoproteins, and that is considered more likely to form plaque in arteries, strongly associated with an increased risk of atherosclerotic cardiovascular disease.
A 1 SDU increase in a concentration of ApoB48, a lipoprotein that transports dietary fat from the intestines and into the bloodstream that also is tied to heart disease and cardiovascular problems, was found to be associated with a 22% decrease in the risk for incident Alzheimer's disease.
Participants in the first quartile of HDL-C, or good cholesterol – in order of lesser amounts – were 44% less likely to develop Alzheimer's compared with those in the second, third and fourth quartiles. And those with small dense LDL-C concentrations below the median were 38% less likely to develop Alzheimer's compared with those with concentrations above the median.
In summary, then, lower small-density bad cholesterol (sdLDL-C) concentrations and higher ApoB48 concentrations were associated with a lower Alzheimer's risk. And individuals with the lowest good cholesterol (HDL-C) concentrations were less likely to develop Alzheimer's compared with the remaining sample.
"These findings underscore links between lipoprotein metabolism pathways and Alzheimer's risk, emphasizing the potential role of blood lipoprotein markers in Alzheimer's risk stratification and of lipid modification strategies in dementia prevention," the researchers concluded.
Association of Blood Lipoprotein Levels With Incident Alzheimer's Disease in Community-Dwelling Individuals: The Framingham Heart Study
Sokratis Charisis, Sophia Lu, Jesus David Melgarejo, Claudia L. Satizabal, Ramachandran S. Vasan, Alexa S. Beiser, Sudha Seshadri
First published: May 30, 2025, in the journal Neurology
Link to full study: https://n.neurology.org/lookup/doi/10.1212/WNL.0000000000213715
The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver of San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of more than $436 million. Driving substantial economic impact with its six professional schools, a diverse workforce of more than 9,400, an annual expense budget of $1.67 billion and clinical practices that provide 2.5 million patient visits each year, UT Health San Antonio plans continued growth over the next five years and anticipates adding more than 1,500 higher-wage jobs to serve San Antonio, Bexar County and the South Texas region. To learn about the many ways "We make lives better®," visit UTHealthSA.org.
The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases is dedicated to providing comprehensive dementia care while advancing treatment through clinical trials and research. The Biggs Institute is a National Institute on Aging (NIA)-designated Alzheimer's Disease Research Center (ADRC). In addition to patient care and research, the Biggs Institute partners with the School of Nursing at UT Health Science Center San Antonio to offer the Caring for the Caregiver program.
Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.
Media Contact
Steven Lee, https://news.uthscsa.edu/, 2104503823, lees22@uthscsa.edu, https://news.uthscsa.edu/
View original content:https://www.prweb.com/releases/ut-health-san-antonio-researchers-discover-new-links-between-heart-disease-and-dementia-302469719.html
SOURCE https://news.uthscsa.edu/

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Zareef Hamid on the Rise of AI-Native Organizations
Zareef Hamid on the Rise of AI-Native Organizations

Yahoo

time39 minutes ago

  • Yahoo

Zareef Hamid on the Rise of AI-Native Organizations

Zareef Hamid explores how AI-native organizations are transforming the nature of business. Harvard MBA and former BCG consultant explores how organizations "built from the ground up" and "architected around AI" are breaking business physics and redefining how work is structured. BOSTON, June 1, 2025 /PRNewswire/ -- Zareef Hamid published "The AI-Native Revolution: How Small Teams Are Redefining Business," documenting how AI-native organizations achieve extraordinary efficiency through fundamental structural changes. Unlike traditional businesses using AI as a tool, these organizations are "built from the ground up" and "architected around AI capabilities from inception." The research reveals startups reaching $10 million in annual recurring revenue within 60 days using teams of just 15-18 people—representing what experts call "superlinear scaling." Revenue per employee figures demonstrate exponential differences: leading AI-powered platforms generate $8.3 million per employee while traditional tech companies manage $2.4 million per employee. This creates "a step-change in how value is created and scaled in the digital economy." The transformation shifts routine tasks to AI systems, enabling human work to focus on creativity, empathy, judgment, and purpose. As routine tasks shift to AI systems, organizations optimize "the partnership between human and machine intelligence." The AI-native revolution isn't replacing humans—it's "redefining how we work together with increasingly intelligent systems." Read the full article here: Contact:***@ Photo(s): Press release distributed by PRLog View original content: SOURCE Zareef Hamid

HORIZON PETROLEUM PROVIDES AN OPERATIONS UPDATE OF ITS PREPARATION FOR FIRST PRODUCTION IN POLAND
HORIZON PETROLEUM PROVIDES AN OPERATIONS UPDATE OF ITS PREPARATION FOR FIRST PRODUCTION IN POLAND

Yahoo

time3 hours ago

  • Yahoo

HORIZON PETROLEUM PROVIDES AN OPERATIONS UPDATE OF ITS PREPARATION FOR FIRST PRODUCTION IN POLAND

CALGARY, AB, June 1, 2025 /PRNewswire/ - Horizon Petroleum Ltd. (the "Company" or "Horizon") (TSXV: HPL) (FRA: HPM) (Tradegate: HPM) is pleased to provide an operations update on progress made towards first production from its cornerstone Lachowice gas development in the Bielsko-Biala concession, southern Poland. David Winter, CEO of the Horizon commented: " We are pleased with the continuing progress in our operations towards first production from the Lachowice 7 well. Board and Management recognise the efforts of our operating team in Poland in ensuring that the initial development program is executed as planned. We also recognise the very positive relationships that we enjoy with our neighbours at Lachowice, and the positive contributions from our contractors, local authorities and government. We look forward to our continuing work with all stakeholders and will update shareholders as the initial development program progresses". Assuming a successful workover result, gas and/or electrical power sales from the Lachowice 7 (L7) well will provide the Company with its first cashflow and will provide a long-term test of the production performance of the naturally fractured, Devonian aged, limestone and dolomite reservoirs in the L7 well. Preparatory work for the L7 workover is progressing on schedule: The Environmental Impact Assessment (EIA) Permit for the L7 workover has been approved by the Ministry of Climate and the Environment (the "Ministry"). With the funds from the recent successful debenture financing, long lead time materials and services have been sourced and ordered with expected deliveries in August and September. These materials include the tubing, wellhead and completion equipment. The Company has received confirmation from its electrical contractor that the local utility company will move the power line that crosses the L7 wellsite by the end of June. Final civil engineering design for the wellsite and access road has been completed and tendering for the construction works to be awarded in the next 3-4 weeks. Wellsite and access road construction to commence in July once the above-mentioned electricity line has been moved. The Company is working with a local service provider to choose the appropriate rig for the workover, now scheduled to commence in September with long-term production testing of the well in October. Early Production System (EPF) The Company continues the work towards finalizing the early production scheme for the initial development at the L7 well following the workover and testing. As previously disclosed, the Company contracted a local electrical engineering company and a mechanical engineering company to review options to monetize gas production from the initial development at L7 and the full field development Lachowice gas field. The reviews and investigations are largely completed: Gas to Power: The company has identified two access points into the local electricity transmission grids. The first with 2MW capacity is located with 300m of the L7 wellsite. The second with 4MW capacity is located approximately 1km from the L7 wellsite. Horizon has made an application to secure the 2MW capacity that will be the first tie-in point for G2P. The company continues to work towards securing the 4MW at the second location. The preliminary design of the gas processing facility that will be required to separate the liquid condensate and any free water from the L7 gas stream has been completed. The Company has commenced sourcing the required vessels and other process equipment. Work on the EIA for the production facility is underway targeting submission in mid-June. Full Field Development Plan The Company has commenced the preliminary work for the EIA for the planned 100km2 3D seismic survey over the Lachowice gas field. A third-party evaluation has identified a high-pressure gas network tie-in point approximately 14 km northeast of L7, half the distance of the previous plan, which will result in reduced pipeline costs and faster approvals. Takeaway capacities have been confirmed and are consistent with Horizon's short and long-term forecast production volumes. The Company has commenced discussions with pipeline operator and owner to secure access and pipeline capacity. The Company will shortly commence the initial work on the EIA for the full field development facility site and commence the process to rezone the land for industrial use. Lachowice 7 Well Workover Operations Program The L7 workover is scheduled to be conducted in September/October of this year subject to receiving the necessary long lead items, equipment and services as planned. A detailed program has been completed and application to the Polish Mining authority for the program will be submitted shortly. The workover program will consist of: Upgrade the wellhead to execute the workover and eventual production. Drill out a surface cement plug and downhole mechanical plug in the wellbore. Pressure test the existing well casing to ensure wellbore security and integrity Drill and recover an existing packer located above the zone that originally tested up to 8.9mmscf/d gas Reperforate, acid stimulation and production test of this same zone Complete the well for production in anticipation of the EPF to be installed on site in first half 2026. The Company is targeting gas/electricity sales and first cash flow by the first half of 2026. About Horizon Petroleum Ltd. Calgary-based Horizon is focused on the appraisal and development of natural gas and oil reserves in Europe. The Management and Board of Horizon consist of oil & gas professionals with significant international experience. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains "forward-looking statements" or "forward-looking information" (collectively referred to herein as "forward-looking statements") within the meaning of applicable securities legislation. Such forward-looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Horizon. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur or be achieved. This press release contains forward-looking statements pertaining to, among other things the timing of re-entry of the well, the moving of the infrastructure in the area, timing of sales gas, and other operational matters in this news release, all of which are subject to change. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Horizon and described in the forward-looking information contained in this press release. Although Horizon believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance. View original content to download multimedia: SOURCE Horizon Petroleum Ltd. Sign in to access your portfolio

Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer

Yahoo

time10 hours ago

  • Yahoo

Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer

Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target CHICAGO, June 1, 2025 /PRNewswire/ -- Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy. These first data on pasritamig, from the first-in-human study, demonstrate that pasritamig appears well-tolerated and exhibits a promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.1 These data were presented as an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology. Pasritamig is a novel T-cell engager designed to bind both CD3 on T-cells and KLK2—a prostate-specific antigen with minimal expression outside of the prostate. Pasritamig activates T-cells by binding to CD3 and directing them to KLK2- expressing tumor cells, engaging the body's immune system to specifically target these cancerous cells. This differentiated approach aims to deliver a targeted treatment for patients with advanced prostate cancer, while potentially reducing the high-grade toxicities historically associated with T-cell engagers. "These first-in-human results for pasritamig are highly encouraging, demonstrating that KLK2 is a viable target for T-cell engagers in metastatic castration-resistant prostate cancer," said Capucine Baldini*, M.D., Ph.D., Drug Development Department (DITEP), Institut Gustave Roussy, and presenting author. "The data show a promising safety profile, with manageable adverse events and no AEs leading to treatment discontinuations or ICANS observed, with 40 percent of patients having no treatment-related AEs at all. Given the limited treatment options for mCRPC, these findings support further investigation of pasritamig and the role of KLK2-targeted T-cell therapies as a potential new approach for patients with aggressive disease." "Metastatic castration-resistant prostate cancer remains one of the most difficult stages of prostate cancer to treat, particularly for patients who haven't responded well to previous treatments," said Jeff Infante, M.D., Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. "This investigational approach underscores our commitment to developing innovative and practice-changing medicines that are well-tolerated and can be easily administered in community practice settings." The Phase 1 first-in-human study (NCT04898634) evaluated 174 patients with ages ranging from 36 to 89 years old and on average having received four prior therapies (range 1-13). The recommended phase 2 dose (RP2D) of pasritamig was 3.5mg on day 1, 18mg on day 8, 300mg intravenously on day 15 and then once every six weeks. The RP2D safety group also included patients treated once every three weeks as the toxicity profiles were very similar. The RP2D efficacy group only included patients treated at the RP2D once every six weeks.1 Within the RP2D safety group (n=45), treated once every three or six weeks, 100 percent had previously received androgen receptor pathway inhibitors, 75.6 percent had undergone taxane chemotherapy, and 37.8 percent had been treated with Lutetium 177 vipivotide tetraxetan prostate-specific membrane antigen radioligand therapy.1 The most common treatment- related adverse events (TRAEs) were Grade 1/2 infusion-related reactions (24.4 percent), Grade 1 cytokine release syndrome (CRS) presenting as fever only (8.9 percent, no steroid or tocilizumab was administered) and no reports of higher grade CRS. No TRAEs leading to treatment discontinuation or dose reduction were reported and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3 TRAEs were infrequent with 4.4 percent of patients reporting transient AST/ALT increases and neutropenia. There were no dose-limiting toxicities reported. The favorable safety profile of the RP2D regimen enabled convenient outpatient administration on a patient-friendly, once-every-six-weeks schedule.1 Of the patients in the RP2D efficacy group (n=33), treated once every six weeks, 42.4 percent achieved a 50 percent or greater reduction in their prostate-specific antigen (PSA) levels with a median rPFS of 7.9 months (95 percent confidence interval [CI] 2.9, not estimable [NE]) and 21.2 percent of patients continuing therapy. Treatment with pasritamig showed durable disease control and rPFS that compares favorably to historical data in heavily pretreated patients with mCRPC.1 Metastatic castration-resistant prostate cancer occurs in a significant portion of prostate cancer patients, with many progressing despite initial therapies.2 Overall survival from diagnosis of mCRPC patients ranges from 13.5 to 31.6 months, and lower in patients who have progressed on therapy.3 Treatment options remain limited, underscoring the urgent need for safer and more effective therapies.4 About Pasritamig (JNJ-78278343)Pasritamig (JNJ-78278343) is an investigational T-cell-engaging bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells and CD3 on T-cells. This approach is being evaluated in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a patient population with limited treatment options. About Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC) is a challenging and aggressive stage of prostate cancer where the disease progresses despite androgen deprivation therapy.2 Patients often experience metastasis to bones and lymph nodes, leading to poor outcomes and limited treatment options, including chemotherapy and second-line hormone therapies.5 The median overall survival ranges from 13.5 to 31.6 months depending on the site of metastasis, with a typical range of 15–36 months across the broader population.3,6 Survival rates can vary significantly depending on factors such as prior treatment history, disease burden, and response to therapy. The need for more effective treatments is critical, as the disease continues to impact a large number of men globally, with mCRPC being responsible for a substantial number of prostate cancer-related deaths. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of JNJ-78278343. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Source: Johnson & Johnson *Dr. Capucine Baldini has provided consulting, advisory, and speaking services to Johnson & Johnson; Dr. Baldini has not been paid for any media work. 1 Baldini, C., et al. Phase 1 Study Results of Pasritamig (JNJ-78278343) in Metastatic Castration-Resistant Prostate Cancer. 2025 American Society of Clinical Oncology Annual Meeting. June 2025.2 Scher, H. I., et al. (2016). "Treatment of castration-resistant prostate cancer: Current and future strategies." Nature Reviews Clinical Oncology, 13(10), 577-590.3 Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365-1374. doi:10.1007/s10552-021-01484-44 Ravi P, Mateo J, Lorente D, et al. Clinical prognostic factors and management of metastatic castration-resistant prostate cancer: a population-based study. PLoS One. 2015;10(10):e0139440. doi:10.1371/ Ryan, C. J., et al. (2015). "Abiraterone acetate in metastatic prostate cancer: A new era." Journal of Clinical Oncology, 33(10), 1051-1060.6 Kawahara, T., Saigusa, Y., Yoneyama, S. et al. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer 23, 214 (2023). Media contacts:Oncology Media Relations oncology_media_relations@ Investor contact:Lauren Johnsoninvestor-relations@ U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: SOURCE Johnson & Johnson Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store